Exiqon to Divest CLIA Lab; Seeks Partners | GenomeWeb

NEW YORK (GenomeWeb News) – Exiqon today said that it will divest its California-based CLIA lab, Oncotech, in an effort to "gain operational and infrastructural efficiencies and to free up human financial resources."

The Vedbaek, Denmark-based molecular diagnostics firm also said that as a consequence of the divestiture it would seek partners to co-develop and commercialize its miRNA-based diagnostic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.